Irinotecan in first line therapy of elderly and non-elderly patients with metastatic colorectal cancer:: Meta-analysis of four trials investigating 5-FU and irinotecan.

被引：0

作者：

Folprecht, G.

Rougier, P.

Saltz, L.

Van Cutsem, E.

Douillard, J. Y.

Sastre, J.

Mitry, E.

Hecker, H.

Schubert, U.

Köhne, C. H.

机构：

[1] Univ Hosp Dresden, Dresden, Germany

[2] Hop Ambroise Pare, Boulogne, France

[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[4] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium

[5] Ctr Rene Gauducheau, St Herblain, France

[6] Hosp Clin San Carlos, Madrid, Spain

[7] Hannover Med Sch, D-3000 Hannover, Germany

[8] Klinikum Oldenburg GmbH, Oldenburg, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3578

引用

页码：165S / 165S

页数：1

共 50 条

[1] Irinotecan in first line therapy of elderly patients with metastatic colorectal cancer:: Metaanalysis of four trials
Folprecht, Gunnar
Rougier, Philippe
Saltz, Leonard
Van Cutsem, Eric
Douillard, Jean-Yves
Sastre, J.
Mitry, Emmanuel
Hecker, Hartmut
Schubert, Ute
Koehne, Claus-Henning
ANNALS OF ONCOLOGY, 2006, 17 : 117 - 117
[2] Efficacy of bolus and infusional 5-FU in elderly and non-elderly patients with metastatic colorectal cancer -: a pooled analysis of clinical trials.
Folprecht, G
Cunningham, D
Glimeilius, B
Dicostanzo, F
Wils, J
Scheithauer, W
Rougier, P
Aranda, E
Pabst, U
Köhne, CH
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 740S - 740S
[3] Capecitabine Plus Irinotecan Versus 5-FU/Leucovorin Plus Irinotecan in the Treatment of Colorectal Cancer: A Meta-analysis
Guo, Yuanbiao
Shi, Min
Shen, Xiaoheng
Yang, Chen
Yang, Liu
Zhang, Jun
CLINICAL COLORECTAL CANCER, 2014, 13 (02) : 110 - 118
[4] SAFETY AND ACTIVITY OF AN ALTERNATINIG REGIMEN OF IRINOTECAN/5-FU/LV AND OXALIPLATIN/5-FU/LV (FAFOXIRI) IN ELDERLY PATIENTS WITH METASTATIC COLORECTAL CANCER (MCC)
Amoroso, Vito
Ferrari, Vittorio
Valcamonico, Francesca
Vassalli, Lucia
Simoncini, Edda
Grisanti, Salvatore
Marpicati, Patrizia
Rangoni, Giovanni
Marini, Giovanni
ANNALS OF ONCOLOGY, 2004, 15 : 62 - 63
[5] Irinotecan/5-FU/FA (I-FU) or 5-FU/FA (FU) first-line therapy in older and younger patients with metastatic colorectal cancer: Combined analysis of 2,691 patients in randomized controlled trials
Folprecht, G.
Seymour, M. T.
Saltz, L.
Douillard, J. Y.
Stephens, R. J.
Van Cutsem, E.
Rougier, P.
Maughan, T. S.
Koehne, C. H.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[6] Efficacy and safety of addition of bevacizumab to FOLFIRI or irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer A meta-analysis
Chen, Ke
Gong, Yinya
Zhang, Qi
Shen, Yanping
Zhou, Taoqi
MEDICINE, 2016, 95 (46)
[7] Second line chemotherapy after first line irinotecan, oxaliplatin and 5-FU/LV (FOLFOXIRI) in metastatic colorectal cancer (MCRC) patients (pts).
Masi, G
Allegrini, G
Marcucci, L
Cupini, S
Brunetti, I
Fontana, E
Ricci, S
Cerri, E
Barbara, C
Falcone, A
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 291S - 291S
[8] Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer
Gunnar Folprecht
Susanne Hamann
Katharina Schütte
Tanja Trarbach
Jan Stoehlmacher-Williams
Gerhard Ehninger
BMC Cancer, 14
[9] Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer
Folprecht, Gunnar
Hamann, Susanne
Schuete, Katharina
Trarbach, Tanja
Stoehlmacher-Williams, Jan
Ehninger, Gerhard
BMC CANCER, 2014, 14
[10] Efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-FU as first-line treatment for patients with metastatic colorectal cancer.
Sobrero, A.
Ackland, S.
Carrion, R. P.
Chiara, S.
Clarke, S.
Giron, C. G.
Langer, B.
Zurlo, A.
Young, S.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 157S - 157S

← 1 2 3 4 5 →